Utilize este identificador para referenciar este registo: https://hdl.handle.net/1822/61429

Registo completo
Campo DCValorIdioma
dc.contributor.authorSeverino, Patriciapor
dc.contributor.authorSilva, Classius F. dapor
dc.contributor.authorAndrade, Luciana N.por
dc.contributor.authorOliveira, Daniele de Limapor
dc.contributor.authorCampos, Joanapor
dc.contributor.authorSouto, Eliana B.por
dc.date.accessioned2019-09-20T07:56:44Z-
dc.date.issued2019-11-
dc.identifier.citationSeverino, Patricia; Silva, Classius F. da; Andrade, Luciana N.; Oliveira, Daniele de Lima; Campos, Joana; Souto, Eliana, Alginate Nanoparticles for Drug Delivery and Targeting. Current Pharmaceutical Design, 25(11), 1312-1334, 2019por
dc.identifier.issn1381-6128por
dc.identifier.urihttps://hdl.handle.net/1822/61429-
dc.description.abstractNanotechnology refers to the control, manipulation, study and manufacture of structures and devices at the nanometer size range. The small size, customized surface, improved solubility and multi-functionality of nanoparticles will continue to create new biomedical applications, as nanoparticles allow to dominate stability, solubility and bioavailability, as well controlled release of drugs. The type of a nanoparticle, and its related chemical, physical and morphological properties influence its interaction with living cells, as well as determine the route of clearance and possible toxic effects. This field requires cross-disciplinary research and gives opportunities to design and develop multifunctional devices, which allow the diagnosis and treatment of devastating diseases. Over the past few decades, biodegradable polymers have been studied for the fabrication of drug delivery systems. There was extensive development of biodegradable polymeric nanoparticles for drug delivery and tissue engineering, in view of their applications in controlling the release of drugs, stabilizing labile molecules from degradation and site-specific drug targeting. The primary aim is to reduce dosing frequency and prolong the therapeutic outcomes. For this purpose, inert excipients should be selected, being biopolymers, e.g. sodium alginate, commonly used in controlled drug delivery. Nanoparticles composed of alginate (known as anionic polysaccharide widely distributed in the cell walls of brown algae which, when in contact with water, forms a viscous gum) have emerged as one of the most extensively characterized biomaterials used for drug delivery and targeting a set of administration routes. Their advantages include not only the versatile physicochemical properties, which allow chemical modifications for site-specific targeting but also their biocompatibility and biodegradation profiles, as well as mucoadhesiveness. Furthermore, mechanical strength, gelation, and cell affinity can be modulated by combining alginate nanoparticles with other polymers, surface tailoring using specific targeting moieties and by chemical or physical cross-linking. However, for every physicochemical modification in the macromolecule/ nanoparticles, a new toxicological profile may be obtained. In this paper, the different aspects related to the use of alginate nanoparticles for drug delivery and targeting have been revised, as well as how their toxicological profile will determine the therapeutic outcome of the drug delivery system.por
dc.description.sponsorshipThe authors acknowledge the financial support received from Portuguese Science and Technology Foundation (FCT/MCT) and from European Funds (PRODER/COMPETE) under the project reference M-ERA-NET/0004/2015-PAIRED, co-financed by FEDER, under the Partnership Agreement PT2020.por
dc.language.isoengpor
dc.publisherBentham Science Publisherspor
dc.rightsrestrictedAccesspor
dc.subjectNanotechnologypor
dc.subjectnanoparticlespor
dc.subjectalginatepor
dc.subjectcytotoxicitypor
dc.subjectdrug deliverypor
dc.subjectsite-specific targetingpor
dc.titleAlginate nanoparticles for drug delivery and targetingpor
dc.typearticle-
dc.peerreviewedyespor
dc.relation.publisherversionhttps://benthamscience.com/journals/current-pharmaceutical-design/por
dc.commentsCEB51994por
oaire.citationStartPage1312por
oaire.citationEndPage1334por
oaire.citationIssue11por
oaire.citationVolume25por
dc.date.updated2019-09-15T12:42:46Z-
dc.identifier.doi10.2174/1381612825666190425163424por
dc.date.embargo10000-01-01-
dc.identifier.pmid31465282por
dc.description.publicationversioninfo:eu-repo/semantics/publishedVersion-
dc.subject.wosScience & Technologypor
sdum.journalCurrent Pharmaceutical Designpor
Aparece nas coleções:CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
document_51994_1.pdf
Acesso restrito!
2,97 MBAdobe PDFVer/Abrir

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID